The MoatNarrow moat

Synektik (SNT) — moat facet

Synektik earns a 46% return on equity from an exclusive contract it does not own and three cyclotrons it does.

Synektik's advantage has three parts, and only one of them is fully its own. The first, and largest, is the exclusive right to sell and service Intuitive's da Vinci robots in seven countries until the end of 203112. Intuitive's products were 44,9% of the group's revenue in the year to September 20253. The second is the installed base that right has produced: 142 robots under Synektik's service at June 20264, generating 374,7 million złoty a year of instruments, accessories and service5. The third is the one it built: three of Poland's nine cyclotrons, making radiopharmaceuticals that cannot be imported6.

Group revenue, year to Sep 2025 (zł m)Intuitive products — 45%Other equipment, IT, service — 48%Radiopharmaceuticals — 7%Intuitive at 44,9% of 681,6; radiopharma external revenue; remainder calculated
Nearly half is the da Vinci franchise.

The first two are strong while the contract lasts. A hospital in Poland that wants a da Vinci, or instruments for the one it has, must buy them from Synektik. More than 800 surgeons in the territory are certified on the system7. The NFZ set the rate for a robotic prostatectomy at twice the laparoscopic one8, and procedures in Poland rose from about 3 thousand to 19,8 thousand in three years910.

But the moat belongs, in the end, to Intuitive. On 1 March 2026 Intuitive paid about $533,1 million to take over its distributors in Italy, Spain and Portugal11. A month earlier it had extended Synektik to 2031 and added Ukraine12. Synektik's advantage is renewed at Intuitive's discretion, and the returns it earns are a measure of how good a distributor it is, not of anything a rival could never copy.

The returns are high because the business needs little capital. The company's return on equity was 46% in the year to September 202513, the equipment segment's EBITDA margin 29,6%14, and almost all profit is paid out15. The radiopharmaceutical business adds a smaller, genuinely owned moat, 52,9 million złoty of segment revenue at a 30,3% EBITDA margin1617.

What the franchise produces can be read in the list of material contracts Synektik announced in its fiscal year to September 2025. It included da Vinci systems for military hospitals in Wrocław, Szczecin, Bydgoszcz and Kraków, the oncology centre in Lublin, university hospitals in Łódź, Kraków, Białystok and Lublin, the Children's Memorial Health Institute in Warsaw, and, through the Czech subsidiary, hospitals in Olomouc, Plzeň, Brno, Prague and Banská Bystrica and the children's institute in Bratislava18. Many of those contracts also covered consumables for two or three years19. The customers are the country's leading public hospitals, and each one is now a user of instruments that only Synektik may sell there.

The scale is small against the supplier's. Intuitive had an installed base of about 11 710 da Vinci systems at June 202620; Synektik's 14221 are about 1,2% of it22. That is the arithmetic of the risk as well as the opportunity: Synektik matters much more to Intuitive's presence in Central Europe than it does to Intuitive's accounts.

The verdict is narrow. The number that would falsify it is the return on equity: a business with a real moat keeps it high as it grows, and this one also depends on Intuitive's next renewal.

Moat trajectory: Holding steady

The contract was extended to 2031; Intuitive is taking other territories direct.

The number that tests this moat
Reported
Return on equity (company definition), year to Sep 2025
46% (43% a year earlier)

Total comprehensive income over closing equity; flattered by paying almost everything out.

Company definition. Equity is small because nearly all profit is distributed, so the ratio overstates the return on the capital a rival would need.
Source: Synektik annual management board report, year to September 2025 ↗
Aspects of the moat
DIG DEEPER 01
The Da Vinci Franchise, on Lease
Synektik's best asset is a lease on someone else's robot, renewed to 2031 in the same quarter Intuitive bought back three other distributors.
DIG DEEPER 02
The Installed Base That Pays Every Quarter
Synektik's instruments and service now earn more than its robot sales, and they grew six-fold while the robot count rose four-fold.
DIG DEEPER 03
Three of Poland's Nine Cyclotrons
Synektik owns three of Poland's nine cyclotrons, a good local business that is a tenth of the group and shrank in the latest quarter.
DIG DEEPER 04
A Tender Machine With a Light Balance Sheet
Synektik wins public tenders with 221 people and hands almost all the profit back; the skill is real and can be hired away.
References
  1. ReportedThe first, and largest, is the exclusive right to sell and service Intuitive's da Vinci robots in seven countries until the end of 2031.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedThe first, and largest, is the exclusive right to sell and service Intuitive's da Vinci robots in seven countries until the end of 2031.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  3. ReportedIntuitive's products were 44,9% of the group's revenue in the year to September 2025.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  4. ReportedThe second is the installed base that right has produced: 142 robots under Synektik's service at June 2026, generating 374,7 million złoty a year of instruments, accessories and service.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  5. ReportedThe second is the installed base that right has produced: 142 robots under Synektik's service at June 2026, generating 374,7 million złoty a year of instruments, accessories and service.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  6. ReportedThe third is the one it built: three of Poland's nine cyclotrons, making radiopharmaceuticals that cannot be imported.
    Synektik annual management board report for the fiscal year to 30 September 2025 - description of the markets: robotic surgery in Poland, PET scanners, cyclotrons and NFZ-funded PET studies. — October 2024 - September 2025 · publ. December 2025 · source ↗
  7. ReportedMore than 800 surgeons in the territory are certified on the system.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  8. ReportedThe NFZ set the rate for a robotic prostatectomy at twice the laparoscopic one, and procedures in Poland rose from about 3 thousand to 19,8 thousand in three years.
    Rynek Zdrowia - report on robotic surgery in Poland in the first half of 2022: five Versius robots against two new da Vinci sites, leasing and pay-per-procedure removing a minimum 10 million złoty outlay, the robotic prostatectomy tariff twice the laparoscopic one, 17 hospitals in three months. — First half of 2022 · publ. 2022 · source ↗
  9. ReportedThe NFZ set the rate for a robotic prostatectomy at twice the laparoscopic one, and procedures in Poland rose from about 3 thousand to 19,8 thousand in three years.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  10. ReportedThe NFZ set the rate for a robotic prostatectomy at twice the laparoscopic one, and procedures in Poland rose from about 3 thousand to 19,8 thousand in three years.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  11. ReportedOn 1 March 2026 Intuitive paid about $533,1 million to take over its distributors in Italy, Spain and Portugal.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11 710 da Vinci systems up 12%; the 1 March 2026 acquisition of the da Vinci and Ion distribution businesses of ab medica, Abex and Excelencia Robótica for approximately $533,1 million in cash, with $279,8 million of intangible and other assets and $218,0 million of goodwill, making Intuitive the direct distributor in Italy, Spain and Portugal). Same document as Intuitive's own _IS_Q226 record. — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  12. ReportedA month earlier it had extended Synektik to 2031 and added Ukraine.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  13. ReportedThe company's return on equity was 46% in the year to September 2025, the equipment segment's EBITDA margin 29,6%, and almost all profit is paid out.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  14. Moat Explorer calcThe company's return on equity was 46% in the year to September 2025, the equipment segment's EBITDA margin 29,6%, and almost all profit is paid out.
    Moat Explorer calculation from Synektik's reported figures (thousands of złoty unless stated). Market value: 352,60 złoty x 8 529 129 shares = 3 007,4 million złoty (about 3,0 billion złoty); at the NBP rate of 3,8570 = $779,7 million (about $780 million). Trailing revenue to June 2026: 681 598,6 - 482 060,1 + 733 427,1 = 932 965,6 (about 933 million złoty). Trailing continuing net profit: 126 019,2 - 85 705,2 + 137 952,7 = 178 266,7; over 8 529 129 shares = 20,90 złoty; P/E 352,60 / 20,90 = 16,9. Equipment and IT segment EBITDA over segment revenue: 187 190,7 / 631 915,5 = 29,6% (FY2025); 143 577,5 / 579 299,1 = 24,8% (FY2024); 98 943,8 / 410 834,1 = 24,1% (FY2023); 29 865,3 / 139 272,7 = 21,4% (FY2022); 18 636,4 / 100 878,6 = 18,5% (FY2021); 19 605,9 / 112 126,1 = 17,5% (FY2019). Radiopharmaceutical segment EBITDA margin: 16 061,3 / 52 937,4 = 30,3% (FY2025); 16 276,6 / 46 615,7 = 34,9% (FY2024). Recurring revenue, trailing: 374,7 / 59,8 = 6,3 times (September 2022 to June 2026); installed base 142 / 37 = 3,8 times. Recurring revenue per year-end robot: 311,3 / 113 = 2,75 million złoty (FY2025); 193,9 / 86 = 2,25 million złoty (FY2024). Procedures per year-end robot, FY2025: Poland 19 800 / 75 = 264; Czechia and Slovakia 12 500 / 38 = 329. Revenue per average employee: 681,6 / 221 = 3,08 million złoty. Export share: 183,7 / 681,6 = 27,0%. Equipment segment share of revenue excluding intragroup sales: 631,1 / 681,6 = 92,6% (about 93%). Intuitive products: 44,9% x 681,6 = 306,0 million złoty; other equipment, IT and service 681,6 - 306,0 - 50,5 = 325,1 million złoty. Synektik market value over the Estonian contract: 3 007,4 / 41 = 73 (roughly seventy). Dividend paid February 2026: 10,75 x 8 529 129 = 91,7 million złoty; dividend per share 10,75 / 0,45 = 23,9 times since 2021. Free cash flow: FY2025 78,3 - 17,4 = 60,9 million złoty; FY2024 89,6 - 44,9 = 44,7 million złoty. IT4KAN price over market value: 4,15 / 3 007,4 = 0,14%. Recurring revenue, April-June 2025: 103,6 / 1,26 = 82,2 million złoty. Backlog plus active offers at June 2026: 44,2 + 160,8 = 205,0 million złoty. NFZ spending per robotic operation: 59 / 2,1 = 28 thousand złoty (2022); 167 / 5,4 = 31 thousand złoty (2023); 300 / 11 = 27 thousand złoty (2024). NFZ-funded PET studies: 96,1 / 89,3 - 1 = 7,6% (about 8%); per scanner 96 100 / 37 = about 2 600. Affidea: 29,0% x 52,9 = 15,3 million złoty, against segment EBITDA of 16,1 million złoty. Synektik's installed base as a share of Intuitive's: 142 / 11 710 = 1,2%. Czech and Slovak installed base: 42 / 16 = 2,6 times. Equipment segment purchases from others: 100 - 80,2 - 6,8 = 13,0%. Years of exclusivity from September 2026 to 31 December 2031: about 5,3. Year-end P/E and P/S (market value at 30 September over net profit and revenue; continuing profit from FY2024): 122,8 / 9,136 = 13,4 and 122,8 / 134,8 = 0,91 (FY2019); 190,2 / 8,811 = 21,6 and 1,52 (FY2020); 252,5 / 8,384 = 30,1 and 1,96 (FY2021); 237,5 / 10,709 = 22,2 and 1,42 (FY2022); 516,9 / 52,452 = 9,9 and 1,16 (FY2023); 1 635,9 / 98,909 = 16,5 and 2,62 (FY2024); 2 149,3 / 126,019 = 17,1 and 3,15 (FY2025); market values from closing prices of 14,40 złoty, 22,30, 29,60, 27,85, 60,60, 191,80 and 252,00 x 8 529 129. — October 2018 - June 2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in Synektik's financial statements, management board reports, factsheet and market data; operands shown in the source line.
  15. ReportedThe company's return on equity was 46% in the year to September 2025, the equipment segment's EBITDA margin 29,6%, and almost all profit is paid out.
    Synektik interim financial statements for 1 October - 31 December 2025 - including the annex extending the da Vinci distribution agreement to 31 December 2031 and adding Ukraine, and the 10,75 złoty dividend. — October - December 2025 · publ. February 2026 · source ↗
  16. ReportedThe radiopharmaceutical business adds a smaller, genuinely owned moat, 52,9 million złoty of segment revenue at a 30,3% EBITDA margin.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
  17. Moat Explorer calcThe radiopharmaceutical business adds a smaller, genuinely owned moat, 52,9 million złoty of segment revenue at a 30,3% EBITDA margin.
    Moat Explorer calculation from Synektik's reported figures (thousands of złoty unless stated). Market value: 352,60 złoty x 8 529 129 shares = 3 007,4 million złoty (about 3,0 billion złoty); at the NBP rate of 3,8570 = $779,7 million (about $780 million). Trailing revenue to June 2026: 681 598,6 - 482 060,1 + 733 427,1 = 932 965,6 (about 933 million złoty). Trailing continuing net profit: 126 019,2 - 85 705,2 + 137 952,7 = 178 266,7; over 8 529 129 shares = 20,90 złoty; P/E 352,60 / 20,90 = 16,9. Equipment and IT segment EBITDA over segment revenue: 187 190,7 / 631 915,5 = 29,6% (FY2025); 143 577,5 / 579 299,1 = 24,8% (FY2024); 98 943,8 / 410 834,1 = 24,1% (FY2023); 29 865,3 / 139 272,7 = 21,4% (FY2022); 18 636,4 / 100 878,6 = 18,5% (FY2021); 19 605,9 / 112 126,1 = 17,5% (FY2019). Radiopharmaceutical segment EBITDA margin: 16 061,3 / 52 937,4 = 30,3% (FY2025); 16 276,6 / 46 615,7 = 34,9% (FY2024). Recurring revenue, trailing: 374,7 / 59,8 = 6,3 times (September 2022 to June 2026); installed base 142 / 37 = 3,8 times. Recurring revenue per year-end robot: 311,3 / 113 = 2,75 million złoty (FY2025); 193,9 / 86 = 2,25 million złoty (FY2024). Procedures per year-end robot, FY2025: Poland 19 800 / 75 = 264; Czechia and Slovakia 12 500 / 38 = 329. Revenue per average employee: 681,6 / 221 = 3,08 million złoty. Export share: 183,7 / 681,6 = 27,0%. Equipment segment share of revenue excluding intragroup sales: 631,1 / 681,6 = 92,6% (about 93%). Intuitive products: 44,9% x 681,6 = 306,0 million złoty; other equipment, IT and service 681,6 - 306,0 - 50,5 = 325,1 million złoty. Synektik market value over the Estonian contract: 3 007,4 / 41 = 73 (roughly seventy). Dividend paid February 2026: 10,75 x 8 529 129 = 91,7 million złoty; dividend per share 10,75 / 0,45 = 23,9 times since 2021. Free cash flow: FY2025 78,3 - 17,4 = 60,9 million złoty; FY2024 89,6 - 44,9 = 44,7 million złoty. IT4KAN price over market value: 4,15 / 3 007,4 = 0,14%. Recurring revenue, April-June 2025: 103,6 / 1,26 = 82,2 million złoty. Backlog plus active offers at June 2026: 44,2 + 160,8 = 205,0 million złoty. NFZ spending per robotic operation: 59 / 2,1 = 28 thousand złoty (2022); 167 / 5,4 = 31 thousand złoty (2023); 300 / 11 = 27 thousand złoty (2024). NFZ-funded PET studies: 96,1 / 89,3 - 1 = 7,6% (about 8%); per scanner 96 100 / 37 = about 2 600. Affidea: 29,0% x 52,9 = 15,3 million złoty, against segment EBITDA of 16,1 million złoty. Synektik's installed base as a share of Intuitive's: 142 / 11 710 = 1,2%. Czech and Slovak installed base: 42 / 16 = 2,6 times. Equipment segment purchases from others: 100 - 80,2 - 6,8 = 13,0%. Years of exclusivity from September 2026 to 31 December 2031: about 5,3. Year-end P/E and P/S (market value at 30 September over net profit and revenue; continuing profit from FY2024): 122,8 / 9,136 = 13,4 and 122,8 / 134,8 = 0,91 (FY2019); 190,2 / 8,811 = 21,6 and 1,52 (FY2020); 252,5 / 8,384 = 30,1 and 1,96 (FY2021); 237,5 / 10,709 = 22,2 and 1,42 (FY2022); 516,9 / 52,452 = 9,9 and 1,16 (FY2023); 1 635,9 / 98,909 = 16,5 and 2,62 (FY2024); 2 149,3 / 126,019 = 17,1 and 3,15 (FY2025); market values from closing prices of 14,40 złoty, 22,30, 29,60, 27,85, 60,60, 191,80 and 252,00 x 8 529 129. — October 2018 - June 2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in Synektik's financial statements, management board reports, factsheet and market data; operands shown in the source line.
  18. ReportedIt included da Vinci systems for military hospitals in Wrocław, Szczecin, Bydgoszcz and Kraków, the oncology centre in Lublin, university hospitals in Łódź, Kraków, Białystok and Lublin, the Children's Memorial Health Institute in Warsaw, and, through the Czech subsidiary, hospitals in Olomouc, Plzeň, Brno, Prague and Banská Bystrica and the children's institute in Bratislava.
    Synektik annual management board report for the fiscal year to 30 September 2025 - operating review: da Vinci systems and procedures, orders, recurring revenue, radiopharmaceutical products and the Baltic expansion. — October 2024 - September 2025 · publ. December 2025 · source ↗
  19. ReportedMany of those contracts also covered consumables for two or three years.
    Synektik annual management board report for the fiscal year to 30 September 2025 - financial review: margins, net debt, return on equity, working capital and deferred income. — October 2024 - September 2025 · publ. December 2025 · source ↗
  20. ReportedIntuitive had an installed base of about 11 710 da Vinci systems at June 2026; Synektik's 142 are about 1,2% of it.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11 710 da Vinci systems up 12%; the 1 March 2026 acquisition of the da Vinci and Ion distribution businesses of ab medica, Abex and Excelencia Robótica for approximately $533,1 million in cash, with $279,8 million of intangible and other assets and $218,0 million of goodwill, making Intuitive the direct distributor in Italy, Spain and Portugal). Same document as Intuitive's own _IS_Q226 record. — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  21. ReportedIntuitive had an installed base of about 11 710 da Vinci systems at June 2026; Synektik's 142 are about 1,2% of it.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - management commentary: orders, backlog, da Vinci systems and procedures, recurring revenue, radiopharmaceutical sales and seasonality. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  22. Moat Explorer calcIntuitive had an installed base of about 11 710 da Vinci systems at June 2026; Synektik's 142 are about 1,2% of it.
    Moat Explorer calculation from Synektik's reported figures (thousands of złoty unless stated). Market value: 352,60 złoty x 8 529 129 shares = 3 007,4 million złoty (about 3,0 billion złoty); at the NBP rate of 3,8570 = $779,7 million (about $780 million). Trailing revenue to June 2026: 681 598,6 - 482 060,1 + 733 427,1 = 932 965,6 (about 933 million złoty). Trailing continuing net profit: 126 019,2 - 85 705,2 + 137 952,7 = 178 266,7; over 8 529 129 shares = 20,90 złoty; P/E 352,60 / 20,90 = 16,9. Equipment and IT segment EBITDA over segment revenue: 187 190,7 / 631 915,5 = 29,6% (FY2025); 143 577,5 / 579 299,1 = 24,8% (FY2024); 98 943,8 / 410 834,1 = 24,1% (FY2023); 29 865,3 / 139 272,7 = 21,4% (FY2022); 18 636,4 / 100 878,6 = 18,5% (FY2021); 19 605,9 / 112 126,1 = 17,5% (FY2019). Radiopharmaceutical segment EBITDA margin: 16 061,3 / 52 937,4 = 30,3% (FY2025); 16 276,6 / 46 615,7 = 34,9% (FY2024). Recurring revenue, trailing: 374,7 / 59,8 = 6,3 times (September 2022 to June 2026); installed base 142 / 37 = 3,8 times. Recurring revenue per year-end robot: 311,3 / 113 = 2,75 million złoty (FY2025); 193,9 / 86 = 2,25 million złoty (FY2024). Procedures per year-end robot, FY2025: Poland 19 800 / 75 = 264; Czechia and Slovakia 12 500 / 38 = 329. Revenue per average employee: 681,6 / 221 = 3,08 million złoty. Export share: 183,7 / 681,6 = 27,0%. Equipment segment share of revenue excluding intragroup sales: 631,1 / 681,6 = 92,6% (about 93%). Intuitive products: 44,9% x 681,6 = 306,0 million złoty; other equipment, IT and service 681,6 - 306,0 - 50,5 = 325,1 million złoty. Synektik market value over the Estonian contract: 3 007,4 / 41 = 73 (roughly seventy). Dividend paid February 2026: 10,75 x 8 529 129 = 91,7 million złoty; dividend per share 10,75 / 0,45 = 23,9 times since 2021. Free cash flow: FY2025 78,3 - 17,4 = 60,9 million złoty; FY2024 89,6 - 44,9 = 44,7 million złoty. IT4KAN price over market value: 4,15 / 3 007,4 = 0,14%. Recurring revenue, April-June 2025: 103,6 / 1,26 = 82,2 million złoty. Backlog plus active offers at June 2026: 44,2 + 160,8 = 205,0 million złoty. NFZ spending per robotic operation: 59 / 2,1 = 28 thousand złoty (2022); 167 / 5,4 = 31 thousand złoty (2023); 300 / 11 = 27 thousand złoty (2024). NFZ-funded PET studies: 96,1 / 89,3 - 1 = 7,6% (about 8%); per scanner 96 100 / 37 = about 2 600. Affidea: 29,0% x 52,9 = 15,3 million złoty, against segment EBITDA of 16,1 million złoty. Synektik's installed base as a share of Intuitive's: 142 / 11 710 = 1,2%. Czech and Slovak installed base: 42 / 16 = 2,6 times. Equipment segment purchases from others: 100 - 80,2 - 6,8 = 13,0%. Years of exclusivity from September 2026 to 31 December 2031: about 5,3. Year-end P/E and P/S (market value at 30 September over net profit and revenue; continuing profit from FY2024): 122,8 / 9,136 = 13,4 and 122,8 / 134,8 = 0,91 (FY2019); 190,2 / 8,811 = 21,6 and 1,52 (FY2020); 252,5 / 8,384 = 30,1 and 1,96 (FY2021); 237,5 / 10,709 = 22,2 and 1,42 (FY2022); 516,9 / 52,452 = 9,9 and 1,16 (FY2023); 1 635,9 / 98,909 = 16,5 and 2,62 (FY2024); 2 149,3 / 126,019 = 17,1 and 3,15 (FY2025); market values from closing prices of 14,40 złoty, 22,30, 29,60, 27,85, 60,60, 191,80 and 252,00 x 8 529 129. — October 2018 - June 2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in Synektik's financial statements, management board reports, factsheet and market data; operands shown in the source line.
Sources
Generated September 24, 2026